409 related articles for article (PubMed ID: 30611527)
41. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel
Taguchi H; Otsuka T; Shimokawa M; Arima S; Hashimoto S; Ido A; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Fukahori M; Makiyama A; Honda T; Shibuki T; Mizuta T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T
Anticancer Res; 2021 Jul; 41(7):3573-3582. PubMed ID: 34230153
[TBL] [Abstract][Full Text] [Related]
42. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Doleh Y; Lal LS; Blauer-Petersen C; Antico G; Pishvaian M
Cancer Med; 2020 May; 9(10):3463-3476. PubMed ID: 32212262
[TBL] [Abstract][Full Text] [Related]
43. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
44. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
45. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW
Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977
[TBL] [Abstract][Full Text] [Related]
46. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Ushida Y; Inoue Y; Oba A; Mie T; Ito H; Ono Y; Sato T; Ozaka M; Sasaki T; Saiura A; Sasahira N; Takahashi Y
Ann Surg Oncol; 2022 Aug; 29(8):5038-5050. PubMed ID: 35294658
[TBL] [Abstract][Full Text] [Related]
47. Conventional chemotherapy of advanced pancreatic cancer.
Giuliani F; Di Maio M; Colucci G; Perrone F
Curr Drug Targets; 2012 Jun; 13(6):795-801. PubMed ID: 22458526
[TBL] [Abstract][Full Text] [Related]
48. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Arciero V; Luo J; Parmar A; Dai WF; Beca JM; Raphael MJ; Isaranuwatchai W; Habbous S; Tadrous M; Earle CC; Biagi JJ; Mittmann N; Arias J; Gavura S; Chan KKW
JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35758620
[TBL] [Abstract][Full Text] [Related]
49. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
[TBL] [Abstract][Full Text] [Related]
50. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
51. Pancreatic Cancer in the Era of Neoadjuvant Therapy: A Narrative Overview.
Casciani F; Marchegiani G; Malleo G; Bassi C; Salvia R
Chirurgia (Bucur); 2018; 113(3):307-317. PubMed ID: 29981662
[TBL] [Abstract][Full Text] [Related]
52. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
[TBL] [Abstract][Full Text] [Related]
53. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
Ahmad SA; Duong M; Sohal DPS; Gandhi NS; Beg MS; Wang-Gillam A; Wade JL; Chiorean EG; Guthrie KA; Lowy AM; Philip PA; Hochster HS
Ann Surg; 2020 Sep; 272(3):481-486. PubMed ID: 32740235
[TBL] [Abstract][Full Text] [Related]
54. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
Carrato A; Vieitez JM; Benavides M; Rodriguez-Garrote M; Castillo A; Ogalla GD; Bermejo LG; Ruiz de Mena I; Guillén-Ponce C; Aranda E;
Eur J Cancer; 2020 Nov; 139():51-58. PubMed ID: 32977220
[TBL] [Abstract][Full Text] [Related]
55. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Ide Y; Otsuka T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Shinohara Y; Ueno S; Taguchi H; Honda T; Shibuki T; Nio K; Ureshino N; Mizuta T; Mitsugi K; Shirakawa T
Anticancer Res; 2023 Apr; 43(4):1817-1826. PubMed ID: 36974805
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
[TBL] [Abstract][Full Text] [Related]
57. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
[TBL] [Abstract][Full Text] [Related]
58. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
Templeton S; Moser M; Wall C; Shaw J; Chalchal H; Luo Y; Zaidi A; Ahmed S
J Gastrointest Cancer; 2021 Jun; 52(2):529-535. PubMed ID: 32440849
[TBL] [Abstract][Full Text] [Related]
59. Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Sigel K; Zhou M; Park YA; Mutetwa T; Nadkarni G; Yeh C; Polak P; Sigel C; Conroy T; Juzyna B; Ychou M; Fojo T; Wisnivesky JP; Bates SE
Semin Oncol; 2021 Feb; 48(1):69-75. PubMed ID: 33714591
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of the Treatment Duration of Japanese Patients With Pancreatic Cancer in a Real-World Setting Using a Large Hospital Claims Database: The SUISEI Study.
Ueno H; Shimizu K; Fukui A; Nii M; Koto R; Unno M
Pancreas; 2024 Jul; 53(6):e492-e500. PubMed ID: 38767967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
